More medical technology muscle or the end of a gravy train? - UK probes private equity
This article was originally published in Clinica
Today sees the start of a crucial stage in the UK parliament's investigation of the private equity sector, which could revolutionise the regulation of buyout operations. From the venture capitalists eyeing the growing medtech start-up buyout market, to the private equity (PE) giants that are behind pan-sectoral UK takeovers worth up to $22bn, all have a vested interest in the outcome.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.